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Abstract As neoadjuvant and adjuvant chemotherapy
schedules often consist of multiple treatment cycles over
relatively long periods of time, it is important to know what
eVects protracted drug administration can have on the
immune system. Here, we studied the long-term eVects of
doxorubicin on the capacity of dendritic cell (DC) precur-
sors to diVerentiate into a particular DC subset, the Langerhans
cells (LC). In order to achieve high telomerase activity as
detected in hematological stem cells, precursor cells from
the acute-myeloid leukemia (AML)-derived cell line
MUTZ3 were stably transduced with human telomerase
reverse transcriptase (hTERT) to facilitate their growth
potential, while preventing growth, and drug-induced
senescence, and preserving their unique capacity for cyto-
kine-dependent DC and LC diVerentiation. The hTERT-
MUTZ3 cells were selected with increasing concentrations
of the anthracyclin doxorubicin. After 1–2 months of selec-
tion with 30–90 nM doxorubicin, the cells completely lost
their capacity to diVerentiate into LC. This inhibition turned
out to be reversible, as the cells slowly regained their
capacity to diVerentiate after a 3- to 4-month drug-free
period and with this became capable again of priming allo-
geneic T cells. Of note, the loss and gain of this capacity to
diVerentiate coincided with the loss and gain of a subpopu-
lation within the CD34+ proliferative compartment with
surface expression of the stem cell factor receptor (SCF-R/
CD117/c-Kit). These data are in favor of cytostatic drug-
free intervals before applying autologous DC-based vacci-
nation protocols, as speciWc DC precursors may need time
to recover from protracted chemotherapy treatment and
re-emerge among the circulating CD34+ hematopoietic
stem and precursor cells.
Keywords Chemotherapy · Doxorubicin · 
Dendritic cell diVerentiation · c-Kit
Introduction
Recent therapeutic advances are turning cancer into a
more chronic disease. With patients being treated on and
oV with cytotoxic drugs in order to control metastasis, the
eVects of such treatment on the immune system in the
long run should be considered. Safeguarding the immune
competence of cancer patients may be vital to their quality
of life as well as overall survival. In addition, successful
application of novel immunotherapies also requires intact
immune eVector functions. Dendritic cells (DC) are the
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main orchestrators of the immune system and have a key
function in linking the innate with the adaptive immune
response  [28, 33]. For autologous DC vaccination strate-
gies, most often patient-derived material is used as a
source of DC precursor cells. We therefore examined
whether a long history of drug exposure could hamper DC
diVerentiation.
The human acute-myeloid leukemia (AML)-derived DC
cell line MUTZ3 [16] can develop either into interstitial DC
(MUTZ3-IDC) by culturing the cells with granulocyte and
macrophage-colony stimulating factor (GM-CSF), tumor
necrosis factor alpha (TNF), and interleukin-4 (IL-4) or
into Langerhans cells (MUTZ3-LC) by culturing the cells
with GM-CSF, TNF, and transforming growth factor beta
(TGF) [21, 22]. Of note, MUTZ-3 DC development accu-
rately reXects all stages observed in its physiological
CD34+ precursor-derived counterparts, and as such, this
cell line presents a relevant and sustainable human DC/LC
diVerentiation [23]. We recently found that short-term
exposure of CD34+ cells, including MUTZ-3, to the cyto-
toxic drugs mitoxantrone or doxorubicin induced acceler-
ated DC and LC diVerentiation with corresponding
functionalities like migration, allogeneic T-cell stimulation,
and cytotoxic T lymphocyte (CTL) priming (van de Ven
et al. manuscript in preparation). These observations sup-
port the use of single-dose cytostatic drugs, as a diVerentiat-
ing agent to facilitate in vitro DC culture for therapeutic
purposes. In this study, we examined the eVect of long-term
drug exposure on the capacity of DC precursor cells to
diVerentiate into functional LC. For these long-term cul-
tures, we made use of MUTZ3 cells that had been stably
transduced with the gene encoding the catalytic subunit of
the telomerase complex, the human telomerase reverse
transcriptase (hTERT), in order to avoid replicative senes-
cence and achieve high passage numbers with maintained
cytokine-dependent diVerentiation ability. Human hemato-
logical precursor cells in vivo also express telomerase [13].
Derivation of this cell line for the Wrst time allowed the in
vitro study of the eVects of truly long-term exposure of
human precursor cells to cytostatic drugs on DC diVerentia-
tion. Drug selection of these CD34+ DC precursors
revealed that the selective loss of a SCF-R/c-KIT+ subpop-
ulation resulted in an inability for LC diVerentiation. After
removal of doxorubicin from the cultures, this subpopula-
tion re-emerged as did the LC diVerentiation capacity.
The regained capacity to diVerentiate after drug removal, as
well as the capacity of high-passage hTERT-MUTZ3 cells
to diVerentiate, rules out an hTERT-induced eVect on LC
diVerentiation. These data strongly suggest that a drug-free
period of adequate length should be allowed for when
autologous DC-based therapies are considered consecutive
to chemotherapy, in order for the required precursors to
recover.
Materials and methods
MUTZ3 and dendritic cell cultures
The AML-derived MUTZ3 cell line was cultured as
described before [21]. In short, MUTZ3 progenitors were
cultured in MEM- (minimum essential medium, Lonza,
Vervier, Belgium) containing 20% fetal calf serum (FCS),
100 IU/ml sodium-penicillin, 100 g/ml streptomycin,
2m ML-glutamine, 50 M -mercaptoethanol (2ME), and
10% 5637 (renal cell carcinoma) conditioned medium
(MUTZ3 routine medium) in 12-well plates (Costar) at a
concentration of 0.2 million cells/ml and were passaged
twice weekly. Langerhans cells (MUTZ3-LC) were cul-
tured from MUTZ-3 progenitors with 10 ng/ml TGF-1
(Biovision, Mountain View, CA), 1,000 IU/ml rhGM-CSF
(Sagramostim, Berlex), and 120 IU/ml TNF (Miltenyi
Biotec, Bergisch Gladbach, Germany) for 10 days to obtain
immature MUTZ3-LC as described previously [30]. Imma-
ture MUTZ3-LC were matured by adding 33% monocyte
condition medium (MCM) and 2,400 IU/ml TNF for 48 h.
Retroviral constructs
The retroviral vector LZRS-hTERT-IRES-NGFR has
been described previously [25]. The NGFR is a truncated
form of the receptor, with no signaling moiety. Retrovi-
ruses were propagated in Phoenix A cells by plasmid DNA
transfection using Lipofectamin 2000 (Invitrogen, Breda,
The Netherlands) in serum-free medium for 3 h. Medium
was refreshed after 24 h, and viral supernatants were har-
vested 48 h post-transfection and were either directly used
for transduction or stored at ¡80°C in 0.5 ml aliquots.
MUTZ3 retroviral transduction
For the generation of MUTZ3 cells expressing hTERT,
MUTZ3 progenitor cells were transduced with the LZRS-
hTERT-IRES-NGFR retrovirus as described before [7,
25]. In short, 0.5 million MUTZ3 progenitor cells were
transferred to Wbronectin-coated (40 g/ml RetroNectin,
Takara, Japan), non-tissue culture–coated plates (BD Bio-
sciences, Heidelberg, Germany) in 0.5 ml viral supernatant
supplemented with 10% 5637 conditioned medium. Plates
were centrifuged for 90 min at 2,000 rpm at 25°C. Cells
were re-transduced with 0.5 ml fresh viral supernatant after
24 h. The retrovirus infected and transduced the CD34+
proliferative progenitor population of the MUTZ3 cell line.
hTERT-MUTZ3 cells were obtained by selecting the
NGFR-positive cells by Xow sorting, and cells were
maintained in MUTZ3 routine medium as described
above. Doxorubicin selection was started by culturing the
hTERT-MUTZ3 cells with 5 nM doxorubicin (AmershamCancer Immunol Immunother (2011) 60:943–951 945
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Pharmacia, Roosendaal, The Netherlands). Cells were pas-
saged twice weekly as described above. Drug concentrations
were gradually increased. DiVerentiation analysis was per-
formed at diVerent time points during selection with 30 nM
(dox30+) and 90 nM (dox90+) cells. Control, non-exposed
hTERT-MUTZ3 cells were kept in culture alongside the
drug-selected cells and were tested for their diVerentiating
capacity using cells with the same passage numbers.
hTERT PCR
RNA was isolated using RNA-Bee (Bio-connect, Huissen,
The Netherlands), following manufacturer’s guidelines.
The RNA concentration was determined on a Nanodrop
spectrophotometer. cDNA synthesis and PCR reaction were
carried out essentially as described before and were per-
formed with 200 ng RNA [5, 26]. Primers and probes for
hTERT and the household control gene U1 small nuclear
ribonucleoprotein-speciWc A protein (SnRNP U1A) were
used as described previously [26]: hTERT forward 5 ! 3
primer: GAAGGCACTGTTCAGCGTGCTCAAC; hTERT
reverse 5 ! 3 primer: GGTTTGATGATGCTGGCGAT
GACC; hTERT probe: GGCGCCTGAGCTGTACTTTGT
CAAGGTGGA. SnRNP U1A forward 5 ! 3 primer:
CAGTATGCCAAGACCGACTCAGA; snRNP U1A
reverse 5 ! 3 primer: GGCCCGGCATGTGGTGCATA
A; snRNP U1A probe: AGAAGAGGAAGCCCAAGAGC
CA. The RT-PCR reaction was performed at 35 cycles.
XTT cytotoxicity assay
Twenty thousand cells were seeded per well in 96-well
round-bottom plates in a volume of 50 l per well in culture
medium. Doxorubicin was diluted to a maximum concen-
tration of 300 nM in culture medium and 1:3 diluted to
120 pM. Fifty microliters of diluted doxorubicin was added
per well in triplicate for each concentration, giving rise to a
doxorubicin range from 0.06 to 150 nM. Cells were
exposed to the drug for 96 h. Cell viability was measured
by adding XTT supplemented with phenazine methosul-
phate (PMS) for 2–4 h, after which optical density was
measured at 450 nm. Cell viability was determined relative
to the control cells to which no doxorubicin had been
added.
Flow cytometry
LC were immunophenotyped using FITC- and/or PE-con-
jugated Mabs directed against CD1a (1:25), CD54 (1:25),
CD80 (1:25), CD86 (1:25), CD40 (1:10) (PharMingen, San
Diego, CA), CD14 (1:25), HLA-DR (1:25), DC-SIGN
(1:10) (BD Biosciences, San Jose, CA), CD83 (1:10),
CD34 (1:10), Langerin (1:10) (Immunotech, Marseille,
France). hTERT MUTZ3 cells, dox90+ and dox90¡ cells
were phenotyped for cytokine receptors using the following
antibodies: CD34-APC, CD116-FITC, CD117-PE (Pharm-
ingen, San Diego, CA), CD14-PerCP_Cy5, and CD123-PE
(BD Biosciences, San Jose, CA). In short, 2.5–5 £ 104 cells
were washed in PBS supplemented with 0.1% BSA and
0.02% NaN3 and incubated with speciWc or corresponding
isotype-matched control Mabs for 30 min at 4°C. Cells
were washed and analyzed with a FACS-Calibur Xow
cytometer (Becton and Dickinson, San Jose, CA) equipped
with CellQuest analysis software, and the results were
expressed as mean or median Xuorescence intensities, the
percentage of positive cells, or the relative ratios of positive
cells compared with the control cultures.
Mixed leukocyte reaction (MLR)
MLR was performed as described [30]. In short, 1 £ 102–
3 £ 104 LC were co-cultured with 1 £ 105 allogeneic
peripheral blood lymphocytes for 4 days in 96-well plates
in IMDM containing 10% human pooled serum (HPS)
(Sanquin, Amsterdam, The Netherlands), 100 IU/ml
sodium penicillin, 100 g/ml streptomycin, 2 mM L-gluta-
mine, and 50 M -mercaptoethanol. At day 4, 2.5 Ci/ml
[3H]-thymidine (6.7 Ci/mmol, MP Biomedicals, Irvine,
CA) was added per well for 16 h. Plates were harvested
onto glass Wber Wltermats (Packard Instruments, Groningen,
The Netherlands) using a Skatron cell harvester (Skatron
Instruments, Norway), and [3H]-thymidine incorporation
was quantiWed using a Topcount NXT Microbetacounter
(Packard, Meriden, CT).
Statistical analysis
Statistical analysis of the data was performed using the
paired or unpaired two-tailed Student’s t test. DiVerences
were considered statistically signiWcant when P < 0.05.
Results
Doxorubicin selection of MUTZ3 cells
The anthracyclin doxorubicin was chosen as a selection
drug to study the eVects of long-term drug exposure on DC
precursor cells, because of its high clinical relevance.
Doxorubicin is widely used to treat a variety of cancer
types, mostly in combination with other cytotoxic drugs, as
in CHOP (cyclophosphamide, doxorubicin (=hydroxyd-
aunorubicin), vincristine (=Oncovin), and prednisone) or
M-VAC (methotrexate, vinblastine, doxorubicin (=Adria-
mycin), and cisplatin) regimens [14, 19, 20, 31, 32]. As a
source of DC precursor cells, we made use of the MUTZ3946 Cancer Immunol Immunother (2011) 60:943–951
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cell line [16] that can be diVerentiated into either interstitial
D C  o r  L C  [ 21,  22]. The IC50 value of doxorubicin in
MUTZ3 cells was determined by means of a XTT cytotox-
icity assay [IC50: 29 § 18.3 nM (n = 3)]. Although the
cells could be cultured in the presence of doxorubicin up to
a concentration of 30 nM, the selected cells displayed mar-
ginal resistance to the drug compared with the parent
MUTZ3 cells when analyzed in a cytotoxicity test (data not
shown) and the 30 nM-selected cells already lost their pro-
liferative capacity after 9 passages. As a consequence,
increasing the concentration of doxorubicin, in order to
generate a drug-resistant, long-term exposed cell line, did
not prove feasible.
The telomerase complex plays a vital role in preventing
replicative senescence. Of note, wtMUTZ3 cells were
found to lack the expression of hTERT mRNA (Fig. 1a),
which might have contributed to the failure to generate a
continuously proliferating, doxorubicin-resistant cell popu-
lation. We therefore generated MUTZ3 progenitor cells sta-
bly expressing hTERT via transduction with a retroviral
construct encoding hTERT (designated hTERT-MUTZ3).
Expression of hTERT (Fig. 1a) allowed for prolonged cul-
ture (and hence longer drug exposure time) while maintain-
ing dependence on exogenous cytokines for diVerentiation
and growth, which is a typical feature of the MUTZ3 cell
line [16,  23]. Moreover, since hTERT is expressed by
hematopoietic stem cells and by hematological tumors [13],
drug exposure of hTERT-positive MUTZ3 cells more
closely resembles physiological in vivo conditions.
Introduction of hTERT into MUTZ3 precursor cells did
not inXuence the sensitivity of the cells for doxorubicin
(Fig. 1b) but did enhance their proliferation rate compared
with non-transduced MUTZ3 cells (average expansion fac-
tor over 3 days 7.8 § 1.3 and 5.7 § 1.7 for hTERT-
MUTZ3 and MUTZ3, respectively (P < 0.02), averaged
over 8 consecutive passages). hTERT-MUTZ3 cells
retained their ability to diVerentiate into CD1a+ Langerin+
LC (Fig. 2a, b). Figure 2c shows the proliferation rate (i.e.
expansion factor over the course of 3 days) of MUTZ3 ver-
sus hTERT-MUTZ3 upon exposure to 30 nM doxorubicin.
Whereas the MUTZ3 cells stopped proliferating after 9 pas-
sages, the hTERT-MUTZ3 cells maintained a relatively
consistent proliferation rate on drug selection for over 160
passages (data shown for the Wrst 50 passages). Of note,
Fig. 1 Telomerase expression and doxorubicin sensitivity of MUTZ3
and hTERT-MUTZ3 cells. a MUTZ3 progenitors and hTERT-
MUTZ3 progenitors were analyzed for telomerase expression by
RT-PCR. b MUTZ3 and hTERT-MUTZ3 progenitors were analyzed
for their sensitivity to the anthracyclin doxorubicin by means of a XTT
assay over 96 h (experiment representative of 3)
Fig. 2 EVects of hTERT introduction on MUTZ3-LC diVerentiation
and proliferation. a Dot plots of Xow cytometric analysis for the
LC-typifying markers CD1a and Langerin on immature LC (iLC) cul-
tures from MUTZ3 (iLC; left) and hTERT-MUTZ3 (hT-iLC; right).
b Average percentages (+standard deviation) of CD14+, CD34+,
CD1a+ and Langerin+ cells within iLC cultures from MUTZ3 or
hTERT-MUTZ3 cells (n =3 ) .  c Progenitor cell proliferation in the
presence of 30 nM doxorubicin. Shown are the passage numbers
against the expansion of the progenitor cells. MUTZ3 progenitor cells
stopped proliferating after 9 passages in the presence of 30 nM doxo-
rubicin, whereas hTERT-MUTZ3 cells could be cultured for over 160
passages (shown are data up to passage 50)Cancer Immunol Immunother (2011) 60:943–951 947
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wtMUTZ3 cells generally display a considerable Xuctua-
tion in expansion factors between passages. The same Xuc-
tuating pattern was observed in the hTERT-MUTZ3 cells
(Fig. 2c).
Doxorubicin selection hampers LC diVerentiation
Doxorubicin concentrations used to condition the progeni-
tor cell cultures were gradually increased, from 5 and
10 nM (Passage (P)22) up to 20 nM (P30), 30 nM (P55)
(dox30+), and 90 nM (P67) (dox90+). The cells were ana-
lyzed for their sensitivity to doxorubicin and their LC
diVerentiation capacity. Dox30+ cells were twofold and
dox90+ cells were eightfold more resistant to doxorubicin
compared with unselected hTERT-MUTZ3 cells (measured
by XTT with P122 and P167). Culturing the cells under
doxorubicin selection signiWcantly aVected their expansion
factors, which were 7.3 § 1.7 for unselected hTERT-
MUTZ3, 5.0 § 2.0 for dox30+, and 1.2 § 2.0 for dox90+
(averaged over 13 passages) (P < 0.02 for both dox30+ and
dox90+). LC diVerentiation from dox30+ to dox90+ cells
was carried out in the absence of doxorubicin, and the non-
exposed hTERT-MUTZ3 control cells were always diVer-
entiated from the same passage number as the drug-
exposed dox30+ and dox90+ cells. Doxorubicin selection
of the progenitor cells had no eVect on the viability of the
cells during LC culture (Fig. 3a). Cellular output after
10 days of diVerentiation (relative to input) was
1.06 § 0.34 [range 0.58–1.35] for hTERT-MUTZ3 and
1.68 § 0.88 [range 0.75–2.75] for dox90+ cells (n =4 ) .
Selection did drastically reduce the capacity of the cells to
diVerentiate into LC, reXected by signiWcantly reduced lev-
els of the LC-typifying markers CD1a and Langerin, as
well as of the co-stimulatory markers CD40 and CD86 and
of the antigen-presenting molecule HLA-DR (Fig. 3b)
(n =3 ;  d i Verentiation induced at P73, P83 and P189, data
shown for dox 90+ cells; similar results were obtained with
the dox30+ cells [data not shown]).
Inhibition of LC diVerentiation by doxorubicin selection 
is reversible
Dox90+ cells were next cultured in the absence of doxoru-
bicin to study whether the doxorubicin-induced inability to
diVerentiate into LC could be reversed. LC diVerentiation
was analyzed after 1, 3, and 4 months of drug deprivation.
Subsequent to diVerentiation, maturation was induced by
addition of a cytokine cocktail, and after 2 days, the capac-
ity of the matured cells to stimulate T-cell proliferation in
an allogeneic (allo)MLR was determined. The diVerentia-
tion capacity of the cells selected with 90 nM doxorubicin
gradually returned after 3 months of drug depletion
(dox90¡ LC), as evidenced by the expression of CD1a and
Langerin (Fig. 4a). The diVerentiated drug-depleted cells
also responded to maturation stimuli, reXected by the
increase in the percentage of cells expressing the matura-
tion marker CD83 (Fig. 4b). Accordingly, their ability to
stimulate T-cell proliferation in an alloMLR also improved.
After 3 and 4 months in the absence of drugs, dox90¡ mLC
showed enhanced T-cell stimulatory abilities compared
Fig. 3 Doxorubicin selection of 
progenitor cells hampers LC 
diVerentiation. a Output of via-
ble hTERT-MUTZ3 and dox90+ 
hTERT-MUTZ3 cells after 
10 days of LC diVerentiation 
b hTERT-MUTZ3 and dox90+ 
hTERT-MUTZ3 cells were 
diVerentiated into immature LC 
following standard culture pro-
tocols and were analyzed for 
phenotypic marker expression 
by Xow cytometry on day 10. 
Shown are the percentages of 
CD1a+ (top left), Langerin+ (top 
middle) and CD40+ (top right) 
cells and the mean Xuorescence 
intensity levels of CD86 (bottom 
left), CD54 (bottom middle), and 
HLA-DR (bottom right) in both 
the hTERT-MUTZ3 and dox90+ 
LC cultures (n =3 ,   P <0 . 0 5 )948 Cancer Immunol Immunother (2011) 60:943–951
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with their continuously drug-selected counterparts, and
after 4 months of drug deprivation, their T-cell stimulatory
capacity even matched that of the parental (passage-
matched) hTERT-mLC (Fig. 4c).
Capacity to diVerentiate coincides with the (re-)expression 
of the SCF-R
As hTERT-MUTZ3 cells remained dependent on exoge-
nous cytokines for their growth and diVerentiation, we stud-
ied the expression of cytokine receptors involved in these
processes on the drug-selected and subsequently drug-
deprived cells, as well as on their unselected, parental
counterparts. As the percentage of CD14+ cells within all
cultures was less than Wve percent, we focused on the
expression of cytokine receptors on the proliferative CD34+
cells. All CD34+ cells within all three cultures expressed
high levels of the IL-3 receptor (CD123), low levels of the
GM-CSF receptor (CD116, 5% positive), and TNF recep-
tors I and II (5% positive) and were negative for the IL-6
receptor (CD126) (data not shown). There was, however, a
striking diVerence in the expression of the stem cell factor
receptor (SCF-R/CD117/c-kit) (Fig. 5a). While 36% of the
parental hTERT-MUTZ3 CD34+ population expressed
the SCF-R, expression of SCF-R was completely lost in the
doxorubicin-selected cells. Of note, CD34+ dox90¡ cells
again displayed normalized SCF-R expression levels, com-
parable to the parental hTERT-MUTZ3 cells (Fig. 5a).
We next analyzed whether the absence of SCF-R-
expressing CD34+ cells within the doxorubicin-selected
cultures could be due to a higher sensitivity to the drug.
When cultured in the presence of increasing concentrations
of doxorubicin for 4 days, both the SCF-R¡ and SCF-R+
CD34+ MUTZ3 cells were found to take up doxorubicin
(Fig. 5b). However, uptake levels for doxorubicin were
higher in SCF-R+ cells compared with SCF-R¡ cells as
determined by the mean Xuorescence index (Fig. 5b).
Moreover, whereas the percentages of cells taking up doxo-
rubicin were comparable, signiWcantly more SCF-R+ cells
than SCF-R¡ cells died over the course of treatment at all
indicated concentrations (Fig. 5c). Of note, sorting the
SCF-R+ from the SCF-R¡ cells within untreated hTERT-
MUTZ3 cultures showed that both populations were
equally capable of diVerentiating into LC and that SCF-R
Fig. 4 Doxorubicin-induced suppression of LC diVerentiation is
reversible. hTERT-MUTZ3 cells, dox90+ cells, and dox90¡ cells
(drug-free) were diVerentiated into immature LC for 10 days after 1, 3,
and 4 months of drug depletion of the dox90¡ cells. a dotplots show-
ing CD1a and Langerin expression on hT-iLC, dox90+ iLC, and
dox90¡ iLC. Upon a drug-free period of at least 3 months, the dox90¡
cells regained their diVerentiation potential. b Percentages of cells
expressing the DC maturation marker CD83 in cultures started 1, 3,
and 4 months after drug depletion of the dox90¡ cells. c MLR was
performed using hT-mLC, dox90+ mLC, and dox90¡ mLC [depleted
for drugs for 1 month (left), 3 months (middle), and 4 months (right)],
to analyze the T-cell stimulatory capacities of the mLCCancer Immunol Immunother (2011) 60:943–951 949
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expression was down-regulated in the isolated SCF-R+
fraction upon culture (two independent experiments: data
not shown). These observations are consistent with the
notion that SCF-R+ cells may constitute an early prolifera-
tive LC precursor pool that can quickly diVerentiate into
SCF-R¡ cells with maintained LC diVerentiation ability
but reduced proliferation capacity, resulting in an ultimate
loss of diVerentiation capacity over time.
Discussion
This study describes a possible consequence of long-term
exposure of DC precursors to cytostatic drugs, interfering
with their capacity to develop into DC. By making use of
hTERT-transduced MUTZ3 cells, we have demonstrated
that prolonged doxorubicin exposure renders CD34+ pre-
cursor cells irresponsive to LC-diVerentiating cytokines.
Fortunately, this detrimental eVect of doxorubicin on the
diVerentiation capacity of DC precursors proved to be a
reversible phenomenon. The cells regained the capacity to
diVerentiate and consequently their capacity to stimulate
T-cell proliferation, after a 3- to 4-month drug-free period.
Although this report focused on LC diVerentiation, we have
made similar observations for diVerentiation of interstitial
DC from long-term doxorubicin-exposed hTERT-MUTZ3
cells (data not shown). Analysis of cytokine receptor
expression patterns on unexposed hTERT-MUTZ3 cells,
doxorubicin-exposed dox90+ hTERT-MUTZ3 cells, and
the dox90¡ hTERT-MUTZ3 cells that had been drug-free
for 4 months revealed altered expression of the SCF-R
(CD117/c-kit). Whereas a subpopulation of CD34+ hTERT-
MUTZ3 cells expressed this receptor, a SCF-R-expressing
population was absent in the doxorubicin-selected cells.
Interestingly, when deprived of doxorubicin, in conjunction
with the regained ability to diVerentiate, the SCF-R+ CD34+
precursor population re-emerged. Sensitivity analysis
showed that SCF-R+ CD34+ precursors were more susceptible
to doxorubicin-induced cell death compared to SCF-R¡
CD34+ precursors.
Fig. 5 Doxorubicin exposure down-regulates SCF-R/c-Kit expression
on CD34+ progenitors. a hTERT-MUTZ3, dox90+, and dox90¡
(4 months drug-free) progenitor cells were analyzed for the expression
of the SCF-R/c-Kit. Continuous exposure to doxorubicin abrogated the
expression of SCF-R/c-Kit on a subset of CD34+ progenitors. SCF-R/
c-Kit expression returned upon drug depletion. b wtMUTZ3 cells were
cultured in the presence of 0, 30, 100, or 300 nM doxorubicin for
4 days. SCF-R+ and SCF-R¡ CD34+ cells were analyzed for their
doxorubicin uptake. Left: percentages of SCF-R¡ (white squares) and
SCF-R+ (black squares) cells positive for doxorubicin after 4 days with
the indicated drug concentrations. Right: doxorubicin uptake in SCF-
R¡ and SCF-R+ cells, determined by the mean Xuorescence index
(doxorubicin mean Xuorescence intensity (FL-2 channel) of drug-ex-
posed cells divided by the mean Xuorescence intensity of non-exposed
(0 nM) cells). *P <0 . 0 5  ( n =3 ) .   c Percentages of SCF-R¡ and SCF-R+
cells that died upon doxorubicin treatment, as determined by Xowcy-
tometric analysis with propidium iodide (PI). *P < 0.05 (n =3 )950 Cancer Immunol Immunother (2011) 60:943–951
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SCF-R+ CD34+ cells have been reported to be present
both in bone marrow and in peripheral blood of healthy
donors and AML patients [4,  6,  8,  12,  15,  17,  27]. In
healthy donors, around 50% of the CD34+ cells have been
reported to express SCF-R (range 19–85%), whereas in
AML patients SCF-R+ cells were found in the majority of
the patients and expression ranged between 3 and 96% of
CD34+ cells co-expressing SCF-R [4, 6, 8, 12, 15, 17, 27].
It has been reported that SCF, the ligand for the SCF-R, in
combination with FLT3-ligand, is crucial for the mainte-
nance of a long-term proliferative pool of CD34+ DC pre-
cursor cells [10]. While blockade of the SCF-R did not
directly inhibit DC diVerentiation from CD34+ precursors,
it did interfere with continued proliferation of a subset of
CD34+ precursors with the ability to diVerentiate into DC.
Hence, the observation that the dox90+ cells lack this SCF-
R+ subpopulation and simultaneously have lost their ability
to diVerentiate suggests that due to chronic doxorubicin
exposure, this DC precursor subset with long-term prolifer-
ative potential is selectively depleted from the general pre-
cursor population. A similar eVect could be expected on the
DC precursors among the circulating hematopoietic stem
and precursor cells (HSPC) in patients treated with this
drug and perhaps with related drugs. Research in patient
groups treated with doxorubicin, or related drugs, is
required to gain more insight into the eVects of repetitive
chemotherapy treatment on the presence and quality of DC
precursor cells in vivo, in order to determine whether
longer drug-free intervals should be considered when
applying chemotherapy regimens prior to DC-based immu-
notherapies. In this regard, the use of allogeneic rather than
autologous DC vaccines should be explored for patients
with a long history of chemotherapy treatment [11].
One could argue that the altered diVerentiation capacity
could be caused by the presence of hTERT in the MUTZ3
cells, which could lead to chromosomal instability and
hence an altered diVerentiation potential [24]. However, it
has been shown that hTERT-transduced T cells can be kept
in culture for many months, without loosing their antigen
speciWcity or their cytotoxic abilities [1]. Furthermore, in
our studies, non-drug-exposed hTERT-MUTZ3 cells were
kept in culture alongside the drug-selected cells and were
used as passage-matched controls in the diVerentiation
studies. Despite the continuous expression of hTERT, these
cells maintained their cytokine dependence for growth and
were still capable of LC diVerentiation at high passage
numbers. Also, the observation that the drug-induced diVer-
entiation defect, along with SCF-R/c-kit expression on
CD34+ cells, could be reversed upon withdrawal of the
drug is additional proof that the observed eVects are hTERT
independent.
The negative eVects of long-term exposure of DC pre-
cursor cells to cytostatic drugs are in sharp contrast with
our own observation that a single low dose of the anthracy-
clin doxorubicin, or the related anthracenedione mitoxan-
trone, at the start of in vitro DC diVerentiation from CD34+
precursor cells strongly promotes and even accelerates
diVerentiation (van de Ven et al. manuscript in prepara-
tion). Also, work by Zitvogel et al. has shown that systemic
doxorubicin treatment can promote anti-tumor responses
due to the release of danger signals like the high mobility
group box 1 protein (HMGB1) released from dying tumor
cells. Release of HMGB1 acts as a maturation signal for
resident DC and promotes tumor antigen presentation to
CD8+ T cells [3,  9,  29]. This notwithstanding, our data
imply that in the long run, repetitive systemic treatment
with cytostatic drugs could be disadvantageous due to its
negative eVect on the expansion of CD34+c-kit+ DC precur-
sor cells.
It is known that cytostatic drugs can induce the expres-
sion of ATP-binding cassette (ABC) transporters like P-
glycoprotein (P-gp; ABCB1), multidrug resistance protein
1 (MRP1; ABCC1), or the breast cancer resistance protein
(BCRP; ABCG2), thereby inducing multidrug resistance in
tumor cells [2, 18]. As the protein expression levels of these
ABC transporters were unaltered in doxorubicin-selected
cells (data not shown), the eVect of progenitor cell selection
with doxorubicin seems ABC transporter independent, and
to be caused mainly by the selective loss of SCF-R/c-kit
expressing, CD34+ DC precursor cells with a high prolifer-
ative capacity and hence with an increased susceptibility to
the DNA damaging eVects of cytostatic drugs such as doxo-
rubicin. Altogether our data suggest that, if feasible, suY-
ciently long drug-free intervals should be included in
chemotherapy regimens in order to allow the immune sys-
tem to recuperate. This is of particular relevance in view of
accumulating evidence for a role of immune functions in
clinical responsiveness to chemotherapy [33]. In addition,
when DC vaccination is being considered, patients with a
long history of chemotherapy treatment should be tested for
their suitability for autologous DC vaccination strategies
(assessment of the presence SCF-R+ CD34+ cells), as their
DC precursor cells might give rise to DC of poor quality.
These patients might actually beneWt more from allogeneic
DC vaccination approaches as recently reviewed by us [11].
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